Urinary single-cell sequencing captures kidney injury and repair processes in human acute kidney injury.

Kidney Int

Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Published: December 2022

Acute kidney injury (AKI) is a major health issue, the outcome of which depends primarily on damage and reparative processes of tubular epithelial cells. Mechanisms underlying AKI remain incompletely understood, specific therapies are lacking and monitoring the course of AKI in clinical routine is confined to measuring urine output and plasma levels of filtration markers. Here we demonstrate feasibility and potential of a novel approach to assess the cellular and molecular dynamics of AKI by establishing a robust urine-to-single cell RNA sequencing (scRNAseq) pipeline for excreted kidney cells via flow cytometry sorting. We analyzed 42,608 single cell transcriptomes of 40 urine samples from 32 patients with AKI and compared our data with reference material from human AKI post-mortem biopsies and published mouse data. We demonstrate that tubular epithelial cells transcriptomes mirror kidney pathology and reflect distinct injury and repair processes, including oxidative stress, inflammation, and tissue rearrangement. We also describe an AKI-specific abundant urinary excretion of adaptive progenitor-like cells. Thus, single cell transcriptomics of kidney cells excreted in urine provides noninvasive, unprecedented insight into cellular processes underlying AKI, thereby opening novel opportunities for target identification, AKI sub-categorization, and monitoring of natural disease course and interventions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.kint.2022.07.032DOI Listing

Publication Analysis

Top Keywords

kidney injury
12
injury repair
8
repair processes
8
acute kidney
8
aki
8
tubular epithelial
8
epithelial cells
8
underlying aki
8
kidney cells
8
single cell
8

Similar Publications

Importance: No large randomized clinical trial has directly compared empagliflozin with dapagliflozin, leaving their comparative effectiveness regarding kidney outcomes unknown.

Objective: To compare kidney outcomes between initiation of empagliflozin vs dapagliflozin in adults with type 2 diabetes who were receiving antihyperglycemic treatment.

Design, Setting, And Participants: This target trial emulation used nationwide, population-based routinely collected Danish health care data to compare initiation of empagliflozin vs dapagliflozin in adults with type 2 diabetes who received antihyperglycemic treatment between June 1, 2014, and October 31, 2020.

View Article and Find Full Text PDF

Acute kidney injury (AKI) is one of the most serious and common complications in the course of sepsis, known for its poor prognosis and high mortality rate. Recently, ferroptosis, as a newly discovered regulatory cell death, might be closely associated with the progression of AKI. METTL14 is a writer of RNA m6A, an abundant epigenetic modification in transcriptome with broad function.

View Article and Find Full Text PDF

Diagnosing alkaptonuria-related nephropathy with urine albumin analysis.

Pediatr Nephrol

January 2025

Faculty of Medicine, Department of Pharmacology, Kırıkkale University, Kırıkkale, Turkey.

Homogentisic acid (HGA) accumulation in alkaptonuria (AKU) causes injuries in various organs including the kidney. We present a case of a 9-year-old girl initially diagnosed with AKU-related nephropathy due to proteinuria found in her urine analyses. Despite 1 month of ramipril treatment, the patient's proteinuria progressed, and as a result, kidney biopsy and nitisinone treatment were planned.

View Article and Find Full Text PDF

Objectives: To report the feasibility of a fluid management practice bundle and describe the pre- vs. post-implementation prevalence and odds of cumulative fluid balance greater than 10% in critically ill pediatric patients with respiratory failure.

Design: Retrospective cohort from May 2022 to December 2022.

View Article and Find Full Text PDF

Kidney organ injury scaling: 2025 update.

J Trauma Acute Care Surg

January 2025

From the Division of Urology, Department of Surgery (S.K., J.B.M.), University of Utah School of Medicine, Salt Lake City, Utah; Department of Surgery (G.T.T.), Scripps Memorial Hospital La Jolla, La Jolla, California; Division of Urology, Department of Surgery (R.M.), University of Toronto, Toronto, Ontario, Canada; Department of Radiology (J.A.G.), University of Washington, Harborview Medical Center, Seattle, Washington; Department of Surgery (C.C.), UC Health Medical Center of the Rockies, Loveland, Colorado; Department of Surgery (K.L.K.), University of California San Francisco Fresno, Fresno, California; Department of Surgery (M.C.), Case Western Reserve University, Cleveland, Ohio; Shock Trauma Center (R.A.K.), University of Maryland School of Medicine, Baltimore, Maryland; Division of Acute Care and Regional General Surgery (N.L.W., B.L.Z.), University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin; and Scott Department of Urology (M.C.), Baylor College of Medicine, Houston, Texas.

The American Association for the Surgery of Trauma initially published the organ injury scaling for the kidney in 1989, which was subsequently updated in 2018. This current American Association for the Surgery of Trauma kidney organ injury scaling update incorporates the latest evidence in diagnosis and management of renal trauma and is based upon a multidisciplinary consensus. These changes reflect the near universal use of computed tomography for renal trauma evaluation and the widespread adoption of conservative management across all grades of renal trauma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!